Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alector, Inc.ALEC · Entity 6051 | Director | June 17, 2026 | June 17, 2026 |
| Chrome Holding Co.ME · Entity 76268 | Director | August 26, 2024 | August 28, 2024 |
| Maze Therapeutics, Inc.MAZE · Entity 1775 | Director | June 08, 2026 | June 10, 2026 |
| Oric Pharmaceuticals, Inc.ORIC · Entity 4765 | Director | May 20, 2021 | May 24, 2021 |
| Xenon Pharmaceuticals Inc.XENE · Entity 2602 | Director | September 16, 2019 | September 18, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alector, Inc.
Report date June 17, 2026 · Filed June 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 134,899 |
Reported balance
After 2026-06-17 transaction · row 1
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 28,700 · Balance 134,899 F1: The reported shares are represented by restricted stock units, or RSUs, which vest on the earlier of (i) June 17, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2036-06-16 | Direct | 9,450 |
Reported balance
After 2026-06-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-17 · Grant · Acquired 9,450 · Balance 9,450 F2: The shares subject to the option vest in 12 equal monthly installments beginning on July 17, 2026, provided that the shares subject to the option will vest in full on the earlier of the one-year anniversary of the date of grant or the date of the Issuer's next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported shares are represented by restricted stock units, or RSUs, which vest on the earlier of (i) June 17, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders.
F2: The shares subject to the option vest in 12 equal monthly installments beginning on July 17, 2026, provided that the shares subject to the option will vest in full on the earlier of the one-year anniversary of the date of grant or the date of the Issuer's next annual meeting of stockholders.
Chrome Holding Co.
Report date August 26, 2024 · Filed August 28, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 895,961 |
Reported balance
After 2024-08-26 transaction · row 1
1 source rowRow 1 · 2024-08-26 · Grant · Acquired 658,485 · Balance 895,961 F1: Restricted stock units ("RSUs") issued pursuant to the 23andMe Holding Co. Amended and Restated Outside Director Compensation Policy effective as of September 6, 2023, all of which vest on the earlier of (a) the first anniversary of the grant date and (b) the date of the issuer's 2025 annual meeting of stockholders. Each RSU represents the contingent right to receive one share of Class A common stock of the issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units ("RSUs") issued pursuant to the 23andMe Holding Co. Amended and Restated Outside Director Compensation Policy effective as of September 6, 2023, all of which vest on the earlier of (a) the first anniversary of the grant date and (b) the date of the issuer's 2025 annual meeting of stockholders. Each RSU represents the contingent right to receive one share of Class A common stock of the issuer.
Maze Therapeutics, Inc.
Report date June 08, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.58 · Expires 2036-06-07 | Direct | 18,000 |
Reported balance
After 2026-06-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-08 · Grant · Acquired 18,000 · Balance 18,000 F1: The option shall vest and be fully exercisable on the earlier of (i) the date of the issuer's 2027 annual stockholders meeting or (ii) June 8, 2027, subject to the reporting person's continued service to the issuer on the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shall vest and be fully exercisable on the earlier of (i) the date of the issuer's 2027 annual stockholders meeting or (ii) June 8, 2027, subject to the reporting person's continued service to the issuer on the vesting date.
Oric Pharmaceuticals, Inc.
Report date May 20, 2021 · Filed May 24, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 39,092 |
Ending reported balance
After 2021-05-24 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2021-05-20 · Sale · Disposed 659 · Balance 40,423 F1: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2: Represents the weighted average share price of an aggregate total of 659 shares sold in the price range of $25.00 to $25.15 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Row 2 · 2021-05-21 · Sale · Disposed 1,231 · Balance 39,192 F1: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3: Represents the weighted average share price of an aggregate total of 1,231 shares sold in the price range of $25.00 to $25.35 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Row 3 · 2021-05-24 · Sale · Disposed 100 · Balance 39,092 F1: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2: Represents the weighted average share price of an aggregate total of 659 shares sold in the price range of $25.00 to $25.15 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3: Represents the weighted average share price of an aggregate total of 1,231 shares sold in the price range of $25.00 to $25.35 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Xenon Pharmaceuticals Inc.
Report date September 16, 2019 · Filed September 18, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.44 · Expires 2029-09-15 | Direct | 15,000 |
Reported balance
After 2019-09-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-09-16 · Grant · Acquired 15,000 · Balance 15,000 F1: One-third of the total shares subject to the Option shall vest on the one year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the two year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the three year anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: One-third of the total shares subject to the Option shall vest on the one year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the two year anniversary of the grant date, one-third of the total shares subject to the Option shall vest on the three year anniversary of the grant date.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
BridgeBio Pharma, Inc.
Report date February 16, 2023 · Filed February 22, 2023
Section 16 reporting ended · disclosed 2023-02-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 53,822 |
Ending reported balance
After 2023-02-16 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-02-16 · Exercise / conversion · Acquired 3,196 · Balance 55,126 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Row 2 · 2023-02-16 · Tax withholding · Disposed 1,304 · Balance 53,822 F2: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 3,196 shares of Common Stock underlying the Reporting Person's RSUs. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 12,783 |
Reported balance
After 2023-02-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-02-16 · Exercise / conversion · Disposed 3,196 · Balance 12,783 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3: The RSUs vest with respect to 1/8th of the underlying shares on May 16, 2022; thereafter, 1/8th of the underlying shares shall vest on a quarterly basis, so that all of the underlying shares shall be vested on February 16, 2024, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 3,196 shares of Common Stock underlying the Reporting Person's RSUs.
F3: The RSUs vest with respect to 1/8th of the underlying shares on May 16, 2022; thereafter, 1/8th of the underlying shares shall vest on a quarterly basis, so that all of the underlying shares shall be vested on February 16, 2024, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date.
DICE Therapeutics, Inc.
Report date August 09, 2023 · Filed August 09, 2023
Section 16 reporting ended · disclosed 2023-08-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-08-09 transaction · row 1
1 source rowRow 1 · 2023-08-09 · Disposition to issuer · Disposed 8,427 · Balance 0 F1: On June 18, 2023, DICE Therapeutics, Inc., a Delaware corporation (the "Issuer" or the "Company") entered into the Agreement and Plan of Merger (the "Merger Agreement"), with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Durning Acquisition Corporation, a Delaware corporation and a direct or indirect wholly owned subsidiary of the Parent (the "Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 9, 2023, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased for $48.00 per share (the "Offer Price"), without interest, less any applicable withholding taxes or (y) automatically converted into the right to receive an amount in cash without interest, equal to the Offer Price, less any applicable withholding taxes. Immediately prior to the Closing, any repurchase rights of the Company or other similar restrictions on the Common Stock fully lapsed and all Common Stock became fully vested. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.00 · Expires 2031-09-14 | Direct | 0 |
Reported balance
After 2023-08-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-08-09 · Disposition to issuer · Disposed 4,357 · Balance 0 F4: Pursuant to the Merger Agreement, each Option to purchase shares of Common Stock that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option"), became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash, without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. Except if the exercise price per share of Common Stock of the Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F3: The Company's Stock Option (the "Option") is fully vested and exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.00 · Expires 2031-09-14 | Direct | 0 |
Reported balance
After 2023-08-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-08-09 · Disposition to issuer · Disposed 9,138 · Balance 0 F4: Pursuant to the Merger Agreement, each Option to purchase shares of Common Stock that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option"), became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash, without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. Except if the exercise price per share of Common Stock of the Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F3: The Company's Stock Option (the "Option") is fully vested and exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.00 · Expires 2031-09-14 | Direct | 0 |
Reported balance
After 2023-08-09 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-08-09 · Disposition to issuer · Disposed 8,261 · Balance 0 F4: Pursuant to the Merger Agreement, each Option to purchase shares of Common Stock that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option"), became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash, without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. Except if the exercise price per share of Common Stock of the Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F5: The Option vests as to 1/36th of the total shares monthly, beginning January 1, 2021, subject to the Reporting Holder's continued service to the Registrant. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.00 · Expires 2031-09-14 | Direct | 0 |
Reported balance
After 2023-08-09 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-08-09 · Disposition to issuer · Disposed 22,600 · Balance 0 F4: Pursuant to the Merger Agreement, each Option to purchase shares of Common Stock that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option"), became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash, without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. Except if the exercise price per share of Common Stock of the Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F6: The Option vests as to 1/48th of the total shares monthly, beginning August 20, 2021, subject to the Reporting Holder's continued service to the Registrant. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.98 · Expires 2032-06-06 | Direct | 0 |
Reported balance
After 2023-08-09 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-08-09 · Disposition to issuer · Disposed 31,250 · Balance 0 F4: Pursuant to the Merger Agreement, each Option to purchase shares of Common Stock that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option"), became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash, without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. Except if the exercise price per share of Common Stock of the Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F3: The Company's Stock Option (the "Option") is fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: On June 18, 2023, DICE Therapeutics, Inc., a Delaware corporation (the "Issuer" or the "Company") entered into the Agreement and Plan of Merger (the "Merger Agreement"), with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Durning Acquisition Corporation, a Delaware corporation and a direct or indirect wholly owned subsidiary of the Parent (the "Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent.
F2: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 9, 2023, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased for $48.00 per share (the "Offer Price"), without interest, less any applicable withholding taxes or (y) automatically converted into the right to receive an amount in cash without interest, equal to the Offer Price, less any applicable withholding taxes. Immediately prior to the Closing, any repurchase rights of the Company or other similar restrictions on the Common Stock fully lapsed and all Common Stock became fully vested.
F3: The Company's Stock Option (the "Option") is fully vested and exercisable.
F4: Pursuant to the Merger Agreement, each Option to purchase shares of Common Stock that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option"), became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash, without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. Except if the exercise price per share of Common Stock of the Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof.
F5: The Option vests as to 1/36th of the total shares monthly, beginning January 1, 2021, subject to the Reporting Holder's continued service to the Registrant.
F6: The Option vests as to 1/48th of the total shares monthly, beginning August 20, 2021, subject to the Reporting Holder's continued service to the Registrant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 17, 2026 Filed Jun 17, 2026 20:05 UTC | Alector, Inc. ALEC · Entity 6051 | GrantStock Option (right to buy) · Derivative | 9,450 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-274128 · ownership.xml · derivative · entry 2 SCHELLER RICHARD H · CIK 0001214133 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,450 Underlying: Common Stock · 9,450 shares Expires 2036-06-16 F2 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments beginning on July 17, 2026, provided that the shares subject to the option will vest in full on the earlier of the one-year anniversary of the date of grant or the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| June 17, 2026 Filed Jun 17, 2026 20:05 UTC | Alector, Inc. ALEC · Entity 6051 | GrantCommon Stock | 28,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-274128 · ownership.xml · nonDerivative · entry 1 SCHELLER RICHARD H · CIK 0001214133 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 134,899 F1 · shares: The reported shares are represented by restricted stock units, or RSUs, which vest on the earlier of (i) June 17, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| June 08, 2026 Filed Jun 10, 2026 20:30 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | GrantStock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $23.58 | $0.00 |
DisclosureSEC source: 0001214133-26-000002 · form4-06102026_080600.xml · derivative · entry 1 SCHELLER RICHARD H · CIK 0001214133 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2036-06-07 F1 · derivative.exercise_date: The option shall vest and be fully exercisable on the earlier of (i) the date of the issuer's 2027 annual stockholders meeting or (ii) June 8, 2027, subject to the reporting person's continued service to the issuer on the vesting date. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 23:08 UTC | Alector, Inc. ALEC · Entity 6051 | GrantCommon Stock | 10,833 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-255990 · ownership.xml · nonDerivative · entry 1 SCHELLER RICHARD H · CIK 0001214133 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,199 F1 · shares: The reported shares are represented by restricted stock units, or RSUs, which vest in 4 equal quarterly installments beginning on June 1, 2026. Read SEC document |
| September 22, 2025 Filed Sep 24, 2025 20:18 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | GrantStock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $23.67 | $0.00 |
DisclosureSEC source: 0001214133-25-000007 · form4-09242025_080927.xml · derivative · entry 1 SCHELLER RICHARD H · CIK 0001214133 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2035-09-21 F1 · derivative.exercise_date: The option shall vest as to 1/9 of the total award monthly with the first tranche vesting on October 1, 2025, subject to the reporting person's continued service to the Issuer on the applicable vesting date. Read SEC document |
| September 15, 2025 Filed Sep 16, 2025 20:26 UTC | Maze Therapeutics, Inc. MAZE · Entity 1775 | SaleCommon Stock | 20,744 | $22.37 | $464,034.98 |
DisclosureSEC source: 0001214133-25-000005 · form4-09162025_080924.xml · nonDerivative · entry 1 SCHELLER RICHARD H · CIK 0001214133 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.14 to $22.585, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 11, 2025 Filed Jun 12, 2025 22:05 UTC | Alector, Inc. ALEC · Entity 6051 | GrantStock Option (right to buy) · Derivative | 9,450 | $0.00 Strike: $1.63 | $0.00 |
DisclosureSEC source: 0000950170-25-085617 · ownership.xml · derivative · entry 2 SCHELLER RICHARD H · CIK 0001214133 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,450 Underlying: Common Stock · 9,450 shares Expires 2035-06-10 F2 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments beginning on July 11, 2025, provided that the shares subject to the option will vest in full on the earlier of the one-year anniversary of the date of grant or the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| June 11, 2025 Filed Jun 12, 2025 22:05 UTC | Alector, Inc. ALEC · Entity 6051 | GrantCommon Stock | 28,700 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-085617 · ownership.xml · nonDerivative · entry 1 SCHELLER RICHARD H · CIK 0001214133 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,366 F1 · shares: The reported shares are represented by restricted stock units, or RSUs, which vest on the earlier of (i) June 11, 2026 or (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| May 02, 2025 Filed May 2, 2025 22:00 UTC | Alector, Inc. ALEC · Entity 6051 | GrantCommon Stock | 15,833 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-062995 · ownership.xml · nonDerivative · entry 1 SCHELLER RICHARD H · CIK 0001214133 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,666 F1 · shares: The reported shares are represented by restricted stock units, or RSUs, which vest in 4 equal quarterly installments beginning on June 1, 2025. Read SEC document |
| August 26, 2024 Filed Aug 28, 2024 16:34 UTC | Chrome Holding Co. ME · Entity 76268 | GrantClass A Common Stock | 658,485 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-038683 · wk-form4_1724877237.xml · nonDerivative · entry 1 SCHELLER RICHARD H · CIK 0001214133 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 895,961 F1 · shares: Restricted stock units ("RSUs") issued pursuant to the 23andMe Holding Co. Amended and Restated Outside Director Compensation Policy effective as of September 6, 2023, all of which vest on the earlier of (a) the first anniversary of the grant date and (b) the date of the issuer's 2025 annual meeting of stockholders. Each RSU represents the contingent right to receive one share of Class A common stock of the issuer. Read SEC document |
| August 22, 2024 Filed Aug 23, 2024 20:05 UTC | Alector, Inc. ALEC · Entity 6051 | SaleCommon Stock | 44,250 | $5.16 | $228,387.53 |
DisclosureSEC source: 0000950170-24-100168 · ownership.xml · nonDerivative · entry 1 SCHELLER RICHARD H · CIK 0001214133 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.045 to $5.230. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff, the issuer, or any security holder of the issuer upon request. Read SEC document |
| August 02, 2024 Filed Oct 10, 2024 20:05 UTC | Alector, Inc. ALEC · Entity 6051 | GrantCommon Stock | 15,833 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-114050 · ownership.xml · nonDerivative · entry 1 SCHELLER RICHARD H · CIK 0001214133 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,833 F1 · shares: The reported shares are represented by restricted stock units, or RSUs, which vest in 4 equal quarterly installments beginning on September 1, 2024. F2 · balance_after: The reported amounts in Column 5 of Table I reflect the Reporting Person's beneficial ownership as of the date of filing this Form 4. Read SEC document |
| June 12, 2024 Filed Jun 12, 2024 20:46 UTC | Alector, Inc. ALEC · Entity 6051 | GrantCommon Stock | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-072515 · ownership.xml · nonDerivative · entry 1 SCHELLER RICHARD H · CIK 0001214133 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,250 F1 · shares: The reported shares are represented by restricted stock units, or RSUs, which vest on the earlier of (i) June 12, 2025 or (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| September 06, 2023 Filed Sep 8, 2023 16:57 UTC | Chrome Holding Co. ME · Entity 76268 | GrantClass A Common Stock | 165,088 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-048806 · doc4.xml · nonDerivative · entry 1 SCHELLER RICHARD H · CIK 0001214133 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 237,476 F1 · shares: Restricted stock units ("RSUs") issued pursuant to the 23andMe Holding Co. Amended and Restated Outside Director Compensation Policy (the "Director Compensation Policy"), all of which vest on the earlier of (a) the first anniversary of the grant date and (b) the date of the issuer's 2024 annual meeting of stockholders. Each RSU represents the contingent right to receive one share of Class A common stock of the issuer. Read SEC document |
| August 09, 2023 Filed Aug 9, 2023 20:29 UTC | DICE Therapeutics, Inc. DICE · Entity 110693 | Disposition to issuerStock Option (right to buy) · Derivative | 31,250 | Not disclosed Strike: $14.98 | Not disclosed |
DisclosureSEC source: 0001209191-23-045175 · doc4.xml · derivative · entry 6 SCHELLER RICHARD H · CIK 0001214133 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 31,250 shares Expires 2032-06-06 F4 · price: Pursuant to the Merger Agreement, each Option to purchase shares of Common Stock that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option"), became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash, without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. Except if the exercise price per share of Common Stock of the Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F3 · derivative.exercise_date: The Company's Stock Option (the "Option") is fully vested and exercisable. Read SEC document |
| August 09, 2023 Filed Aug 9, 2023 20:29 UTC | DICE Therapeutics, Inc. DICE · Entity 110693 | Disposition to issuerStock Option (right to buy) · Derivative | 22,600 | Not disclosed Strike: $17.00 | Not disclosed |
DisclosureSEC source: 0001209191-23-045175 · doc4.xml · derivative · entry 5 SCHELLER RICHARD H · CIK 0001214133 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,600 shares Expires 2031-09-14 F4 · price: Pursuant to the Merger Agreement, each Option to purchase shares of Common Stock that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option"), became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash, without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. Except if the exercise price per share of Common Stock of the Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F6 · derivative.exercise_date: The Option vests as to 1/48th of the total shares monthly, beginning August 20, 2021, subject to the Reporting Holder's continued service to the Registrant. Read SEC document |
| August 09, 2023 Filed Aug 9, 2023 20:29 UTC | DICE Therapeutics, Inc. DICE · Entity 110693 | Disposition to issuerStock Option (right to buy) · Derivative | 8,261 | Not disclosed Strike: $17.00 | Not disclosed |
DisclosureSEC source: 0001209191-23-045175 · doc4.xml · derivative · entry 4 SCHELLER RICHARD H · CIK 0001214133 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,261 shares Expires 2031-09-14 F4 · price: Pursuant to the Merger Agreement, each Option to purchase shares of Common Stock that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option"), became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash, without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. Except if the exercise price per share of Common Stock of the Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F5 · derivative.exercise_date: The Option vests as to 1/36th of the total shares monthly, beginning January 1, 2021, subject to the Reporting Holder's continued service to the Registrant. Read SEC document |
| August 09, 2023 Filed Aug 9, 2023 20:29 UTC | DICE Therapeutics, Inc. DICE · Entity 110693 | Disposition to issuerStock Option (right to buy) · Derivative | 9,138 | Not disclosed Strike: $17.00 | Not disclosed |
DisclosureSEC source: 0001209191-23-045175 · doc4.xml · derivative · entry 3 SCHELLER RICHARD H · CIK 0001214133 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,138 shares Expires 2031-09-14 F4 · price: Pursuant to the Merger Agreement, each Option to purchase shares of Common Stock that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option"), became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash, without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. Except if the exercise price per share of Common Stock of the Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F3 · derivative.exercise_date: The Company's Stock Option (the "Option") is fully vested and exercisable. Read SEC document |
| August 09, 2023 Filed Aug 9, 2023 20:29 UTC | DICE Therapeutics, Inc. DICE · Entity 110693 | Disposition to issuerStock Option (right to buy) · Derivative | 4,357 | Not disclosed Strike: $17.00 | Not disclosed |
DisclosureSEC source: 0001209191-23-045175 · doc4.xml · derivative · entry 2 SCHELLER RICHARD H · CIK 0001214133 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,357 shares Expires 2031-09-14 F4 · price: Pursuant to the Merger Agreement, each Option to purchase shares of Common Stock that was outstanding but not vested as of immediately prior to the Closing (the "Unvested Option"), became fully vested and exercisable (the "Vested Option"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash, without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. Except if the exercise price per share of Common Stock of the Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof. F3 · derivative.exercise_date: The Company's Stock Option (the "Option") is fully vested and exercisable. Read SEC document |
| August 09, 2023 Filed Aug 9, 2023 20:29 UTC | DICE Therapeutics, Inc. DICE · Entity 110693 | Disposition to issuerCommon Stock | 8,427 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-045175 · doc4.xml · nonDerivative · entry 1 SCHELLER RICHARD H · CIK 0001214133 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: On June 18, 2023, DICE Therapeutics, Inc., a Delaware corporation (the "Issuer" or the "Company") entered into the Agreement and Plan of Merger (the "Merger Agreement"), with Eli Lilly and Company, an Indiana corporation (the "Parent"), and Durning Acquisition Corporation, a Delaware corporation and a direct or indirect wholly owned subsidiary of the Parent (the "Merger Sub"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (such merger and the other transactions contemplated by the Merger Agreement, the "Merger") with the Company surviving the Merger as a wholly owned subsidiary of the Parent. F2 · price: (Continued from Footnote 1) Upon the closing (the "Closing") of the Merger on August 9, 2023, each share of the Company's Common Stock, par value $0.0001 per share ("Common Stock"), was either (x) purchased for $48.00 per share (the "Offer Price"), without interest, less any applicable withholding taxes or (y) automatically converted into the right to receive an amount in cash without interest, equal to the Offer Price, less any applicable withholding taxes. Immediately prior to the Closing, any repurchase rights of the Company or other similar restrictions on the Common Stock fully lapsed and all Common Stock became fully vested. Read SEC document |
| July 15, 2023 Filed Feb 14, 2024 22:58 UTC | Alector, Inc. ALEC · Entity 6051 | GrantCommon Stock | 8,541 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-015412 · ownership.xml · nonDerivative · entry 1 SCHELLER RICHARD H · CIK 0001214133 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,250 F1 · shares: The reported shares are represented by restricted stock units, or RSUs, which vest as to 50% of the shares on September 1, 2023, as to 25% of the shares on December 1, 2023, and as to the remaining shares on March 1, 2024, provided the Reporting Person continues to serve as a consultant under the terms of the consulting agreement between the Reporting Person and the Issuer. Read SEC document |
| June 14, 2023 Filed Jun 15, 2023 20:02 UTC | Alector, Inc. ALEC · Entity 6051 | GrantStock Option (right to buy) · Derivative | 12,360 | $0.00 Strike: $7.71 | $0.00 |
DisclosureSEC source: 0000950170-23-028270 · ownership.xml · derivative · entry 2 SCHELLER RICHARD H · CIK 0001214133 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,360 Underlying: Common Stock · 12,360 shares Expires 2033-06-14 F2 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments beginning on July 14, 2023, provided that the shares subject to the option will vest in full on the earlier of the one-year anniversary of the date of grant or the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| June 14, 2023 Filed Jun 15, 2023 20:02 UTC | Alector, Inc. ALEC · Entity 6051 | GrantCommon Stock | 26,250 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-028270 · ownership.xml · nonDerivative · entry 1 SCHELLER RICHARD H · CIK 0001214133 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,709 F1 · shares: The reported shares are represented by restricted stock units, or RSUs, which vest on the earlier of (i) June 14, 2024 or (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| May 05, 2023 Filed May 9, 2023 22:02 UTC | DICE Therapeutics, Inc. DICE · Entity 110693 | SaleCommon Stock | 84,097 | $38.51 | $3,238,205.44 |
DisclosureSEC source: 0001209191-23-028355 · doc4.xml · nonDerivative · entry 1 SCHELLER RICHARD H · CIK 0001214133 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,427 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2022. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.50 to $38.61 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 16, 2023 Filed Feb 22, 2023 01:21 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 3,196 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-011457 · doc4.xml · derivative · entry 3 SCHELLER RICHARD H · CIK 0001214133 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,783 Underlying: Common Stock · 3,196 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: The RSUs vest with respect to 1/8th of the underlying shares on May 16, 2022; thereafter, 1/8th of the underlying shares shall vest on a quarterly basis, so that all of the underlying shares shall be vested on February 16, 2024, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date. F3 · derivative.expiration_date: The RSUs vest with respect to 1/8th of the underlying shares on May 16, 2022; thereafter, 1/8th of the underlying shares shall vest on a quarterly basis, so that all of the underlying shares shall be vested on February 16, 2024, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date. Read SEC document |
| February 16, 2023 Filed Feb 22, 2023 01:21 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Tax withholdingCommon Stock | 1,304 | $12.64 | $16,482.56 |
DisclosureSEC source: 0001209191-23-011457 · doc4.xml · nonDerivative · entry 2 SCHELLER RICHARD H · CIK 0001214133 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,822 F2 · shares: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 3,196 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document |
| February 16, 2023 Filed Feb 22, 2023 01:21 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 3,196 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-011457 · doc4.xml · nonDerivative · entry 1 SCHELLER RICHARD H · CIK 0001214133 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,126 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| November 16, 2022 Filed Nov 18, 2022 23:38 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 3,196 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-057983 · doc4.xml · derivative · entry 3 SCHELLER RICHARD H · CIK 0001214133 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,979 Underlying: Common Stock · 3,196 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: The RSUs vest with respect to 1/8th of the underlying shares on May 16, 2022; thereafter, 1/8th of the underlying shares shall vest on a quarterly basis, so that all of the underlying shares shall be vested on February 16, 2024, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date. F3 · derivative.expiration_date: The RSUs vest with respect to 1/8th of the underlying shares on May 16, 2022; thereafter, 1/8th of the underlying shares shall vest on a quarterly basis, so that all of the underlying shares shall be vested on February 16, 2024, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date. Read SEC document |
| November 16, 2022 Filed Nov 18, 2022 23:38 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Tax withholdingCommon Stock | 1,106 | $9.64 | $10,661.84 |
DisclosureSEC source: 0001209191-22-057983 · doc4.xml · nonDerivative · entry 2 SCHELLER RICHARD H · CIK 0001214133 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,930 F2 · shares: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 3,196 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document |
| November 16, 2022 Filed Nov 18, 2022 23:38 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 3,196 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-057983 · doc4.xml · nonDerivative · entry 1 SCHELLER RICHARD H · CIK 0001214133 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,036 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| November 11, 2022 Filed Nov 14, 2022 16:38 UTC | Chrome Holding Co. ME · Entity 76268 | SaleClass A Common Stock | 18,421 | $3.24 | $59,684.04 |
DisclosureSEC source: 0001209191-22-056631 · doc4.xml · nonDerivative · entry 1 SCHELLER RICHARD H · CIK 0001214133 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,388 F1 · price: The sale price reported in Column 4 of Table 1 represents the weighted average sale price of the shares sold ranging from $3.12 to $3.42. Upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| September 06, 2022 Filed Sep 8, 2022 16:47 UTC | Chrome Holding Co. ME · Entity 76268 | GrantClass A Common Stock | 14,633 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-049184 · doc4.xml · nonDerivative · entry 1 SCHELLER RICHARD H · CIK 0001214133 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,809 F1 · shares: Restricted stock units, or RSUs, issued pursuant to the 23andMe Holding Co. Amended and Restated Outside Director Compensation Policy, all of which vest on the earlier of (a) the first anniversary of the grant date or (b) the date of the issuer's 2023 annual meeting of stockholders. Each RSU represents the contingent right to receive one share of Class A common stock of the issuer. Read SEC document |
| August 25, 2022 Filed Aug 29, 2022 16:29 UTC | Chrome Holding Co. ME · Entity 76268 | GrantClass A Common Stock | 57,755 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-047864 · doc4.xml · nonDerivative · entry 1 SCHELLER RICHARD H · CIK 0001214133 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,176 F1 · shares: Restricted stock units, or RSUs, issued pursuant to the 23andMe Holding Co. Amended and Restated Outside Director Compensation Policy, all of which vest on the earlier of (a) the first anniversary of the grant date or (b) the date of the issuer's 2023 annual meeting of stockholders. Each RSU represents the contingent right to receive one share of Class A common stock of the issuer. Read SEC document |
| August 16, 2022 Filed Aug 18, 2022 22:35 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 3,196 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-046733 · doc4.xml · derivative · entry 3 SCHELLER RICHARD H · CIK 0001214133 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,175 Underlying: Common Stock · 3,196 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: The RSUs vest with respect to 1/8th of the underlying shares on May 16, 2022; thereafter, 1/8th of the underlying shares shall vest on a quarterly basis, so that all of the underlying shares shall be vested on February 16, 2024, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date. F3 · derivative.expiration_date: The RSUs vest with respect to 1/8th of the underlying shares on May 16, 2022; thereafter, 1/8th of the underlying shares shall vest on a quarterly basis, so that all of the underlying shares shall be vested on February 16, 2024, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date. Read SEC document |
| August 16, 2022 Filed Aug 18, 2022 22:35 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Tax withholdingCommon Stock | 1,101 | $11.08 | $12,199.08 |
DisclosureSEC source: 0001209191-22-046733 · doc4.xml · nonDerivative · entry 2 SCHELLER RICHARD H · CIK 0001214133 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,840 F2 · shares: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 3,196 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document |
| August 16, 2022 Filed Aug 18, 2022 22:35 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 3,196 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-046733 · doc4.xml · nonDerivative · entry 1 SCHELLER RICHARD H · CIK 0001214133 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,941 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 20:36 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantStock Option (right to buy) · Derivative | 104,921 | $0.00 Strike: $8.45 | $0.00 |
DisclosureSEC source: 0001209191-22-039265 · doc4.xml · derivative · entry 1 SCHELLER RICHARD H · CIK 0001214133 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,921 Underlying: Common Stock · 104,921 shares Expires 2032-06-22 F1 · derivative.exercise_date: 1/3rd of the shares underlying the option will vest on June 22, 2023; thereafter, 1/3rd of the remaining underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on the June 22, 2025, subject to the optionee's continued service on the Board of Directors of the Company. Read SEC document |
| June 16, 2022 Filed Jun 22, 2022 00:06 UTC | Alector, Inc. ALEC · Entity 6051 | GrantStock Option (right to buy) · Derivative | 18,918 | $0.00 Strike: $8.07 | $0.00 |
DisclosureSEC source: 0001209191-22-038571 · doc4.xml · derivative · entry 2 SCHELLER RICHARD H · CIK 0001214133 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,918 Underlying: Common Stock · 18,918 shares Expires 2032-06-16 F2 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments beginning on July 16, 2022, or if earlier, the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| June 16, 2022 Filed Jun 22, 2022 00:06 UTC | Alector, Inc. ALEC · Entity 6051 | GrantCommon Stock | 9,459 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-038571 · doc4.xml · nonDerivative · entry 1 SCHELLER RICHARD H · CIK 0001214133 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,459 F1 · shares: The reported shares are represented by restricted stock units, or RSUs, which vest on the earlier of (i) June 16, 2023 or (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| June 07, 2022 Filed Jun 8, 2022 20:48 UTC | DICE Therapeutics, Inc. DICE · Entity 110693 | GrantStock Option (right to buy Common Stock) · Derivative | 31,250 | $0.00 Strike: $14.98 | $0.00 |
DisclosureSEC source: 0001209191-22-035066 · doc4.xml · derivative · entry 1 SCHELLER RICHARD H · CIK 0001214133 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,250 Underlying: Common Stock · 31,250 shares Expires 2032-06-06 F1 · derivative.exercise_date: The option vests on the earlier to occur of: (i) the one-year anniversary of the grant date and (ii) the subsequent annual meeting of the Registrant's stockholders, in each case, subject to the Reporting Holder's continued service to the Registrant. Read SEC document |
| May 16, 2022 Filed May 18, 2022 20:09 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 3,195 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-018595 · doc4.xml · derivative · entry 3 SCHELLER RICHARD H · CIK 0001214133 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,371 Underlying: Common Stock · 3,195 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: The RSUs vest with respect to 1/8th of the underlying shares on May 16, 2022; thereafter, 1/8th of the underlying shares shall vest on a quarterly basis, so that all of the underlying shares shall be vested on February 16, 2024, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date. F3 · derivative.expiration_date: The RSUs vest with respect to 1/8th of the underlying shares on May 16, 2022; thereafter, 1/8th of the underlying shares shall vest on a quarterly basis, so that all of the underlying shares shall be vested on February 16, 2024, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date. Read SEC document |
| May 16, 2022 Filed May 18, 2022 20:09 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Tax withholdingCommon Stock | 1,310 | $6.74 | $8,829.40 |
DisclosureSEC source: 0000899243-22-018595 · doc4.xml · nonDerivative · entry 2 SCHELLER RICHARD H · CIK 0001214133 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,745 F2 · shares: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 3,195 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document |
| May 16, 2022 Filed May 18, 2022 20:09 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 3,195 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-018595 · doc4.xml · nonDerivative · entry 1 SCHELLER RICHARD H · CIK 0001214133 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,055 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| February 28, 2022 Filed Mar 15, 2022 21:37 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantRestricted Stock Units · Derivative | 25,566 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-011088 · doc4.xml · derivative · entry 1 SCHELLER RICHARD H · CIK 0001214133 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,566 Underlying: Common Stock · 25,566 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: The RSUs vest with respect to 1/8th of the underlying shares on May 16, 2022; thereafter, 1/8th of the underlying shares shall vest on a quarterly basis, so that all of the underlying shares shall be vested on February 16, 2024, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date. F2 · derivative.expiration_date: The RSUs vest with respect to 1/8th of the underlying shares on May 16, 2022; thereafter, 1/8th of the underlying shares shall vest on a quarterly basis, so that all of the underlying shares shall be vested on February 16, 2024, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date. Read SEC document |
| December 02, 2021 Filed Dec 7, 2021 01:55 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantStock Option (right to buy) · Derivative | 16,685 | $0.00 Strike: $40.03 | $0.00 |
DisclosureSEC source: 0000899243-21-047030 · doc4.xml · derivative · entry 2 SCHELLER RICHARD H · CIK 0001214133 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,685 Underlying: Common Stock · 16,685 shares Expires 2031-12-01 F1 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the underlying shares on December 2, 2022 and thereafter in 36 equal monthly installments, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. Read SEC document |
| December 02, 2021 Filed Dec 7, 2021 01:55 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantStock Option (right to buy) · Derivative | 28,881 | $0.00 Strike: $40.03 | $0.00 |
DisclosureSEC source: 0000899243-21-047030 · doc4.xml · derivative · entry 1 SCHELLER RICHARD H · CIK 0001214133 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,881 Underlying: Common Stock · 28,881 shares Expires 2031-12-01 Read SEC document |
| September 14, 2021 Filed Sep 16, 2021 16:24 UTC | Chrome Holding Co. ME · Entity 76268 | GrantClass A Common Stock, $0.0001 par value | 18,421 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-056395 · doc4.xml · nonDerivative · entry 1 SCHELLER RICHARD H · CIK 0001214133 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,421 F1 · shares: The shares are represented by restricted stock units, or RSUs, all of which shall vest in full on the earlier of (a) the first anniversary of the grant date or (b) the date of the issuer's 2022 annual meeting of stockholders. Each RSU represents the contingent right to receive one share of Class A common stock of the issuer. Read SEC document |
| September 14, 2021 Filed Sep 17, 2021 01:26 UTC | DICE Therapeutics, Inc. DICE · Entity 110693 | GrantStock Option (right to buy) · Derivative | 5,600 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001209191-21-056524 · doc4.xml · derivative · entry 7 SCHELLER RICHARD H · CIK 0001214133 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,600 Underlying: Common Stock · 5,600 shares Expires 2031-09-14 F6 · derivative.exercise_date: The option vests as to 1/48th of the total shares monthly, beginning August 20, 2021, subject to the Reporting Holder's continued service to the Registrant. Read SEC document |
| September 14, 2021 Filed Sep 17, 2021 01:26 UTC | DICE Therapeutics, Inc. DICE · Entity 110693 | GrantStock Option (right to buy) · Derivative | 8,500 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001209191-21-056524 · doc4.xml · derivative · entry 6 SCHELLER RICHARD H · CIK 0001214133 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,500 Underlying: Common Stock · 8,500 shares Expires 2031-09-14 F6 · derivative.exercise_date: The option vests as to 1/48th of the total shares monthly, beginning August 20, 2021, subject to the Reporting Holder's continued service to the Registrant. Read SEC document |
| September 14, 2021 Filed Sep 17, 2021 01:26 UTC | DICE Therapeutics, Inc. DICE · Entity 110693 | GrantStock Option (right to buy) · Derivative | 8,500 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001209191-21-056524 · doc4.xml · derivative · entry 5 SCHELLER RICHARD H · CIK 0001214133 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,500 Underlying: Common Stock · 8,500 shares Expires 2031-09-14 F6 · derivative.exercise_date: The option vests as to 1/48th of the total shares monthly, beginning August 20, 2021, subject to the Reporting Holder's continued service to the Registrant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.